Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Abolish Off-Year Revisions, No to Broader CEA Use: Eto Group to Ministers
A group of Liberal Democratic Party (LDP) lawmakers studying pharma industry policies, dubbed the Eto study group, on June 5 submitted a proposal to the health and finance ministers, pushing for the abolishment of “off-year” drug price revisions. In the…
To read the full story
Related Article
- LDP Pharma Study Group’s Final Proposal Urges Raising of Social Security Budget Ceiling
May 29, 2025
- LDP Group Proposes Higher Cap on Social Security Budgets, Category-Based Drug Pricing
May 14, 2025
- LDP’s Pharma Study Group Likely to Stay Even after Its Chair Bows Out
April 16, 2025
- LDP Study Group Urges Health, Finance Ministers to Drop Off-Year Revisions
December 11, 2024
- LDP Pharma Study Group Renews Call for Ditching Off-Year Revisions
December 3, 2024
- LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
- LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
May 22, 2024
- Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
- LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
- Pharma Groups Lobby Firmly against Expansion of CEA Price Adjustments: LDP Hearing
December 4, 2023
REGULATORY
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…